Galderma / Mirvaso
BRIMONIDINE TOPICAL GEL 0.33%
The other approved treatment for rosacea redness, and on paper roughly twice as effective as the one at R-41. Its own label also records subjects whose erythema came back worse than it started. That sentence is the whole review.
There is a real reason to hesitate. Read the finding before you buy.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
We earn nothing on this link. Read the rebound paragraph before you fill this, and agree in advance what you do if your redness comes back worse.
The verdict
R-41 noted that only two drugs are approved for the persistent erythema of rosacea and reviewed one of them. This is the other, and it is the older and, by the numbers, the stronger. Two-grade composite success on day 29 ran from 18% to 31% across four timepoints in two trials, against 9% to 11% on vehicle. Rhofade's equivalent figures, on an endpoint constructed the same way, were 12% to 18%.
So the sensible expectation would be that Mirvaso is the better choice, and the label is the reason it is not. In section 5, plainly: 'Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline.' Not a forum report, not a case series — the registration trials, in the approved labelling.
The adverse reaction table shows the same thing from the other direction. Erythema was reported by 4% of treated subjects against 1% on vehicle, and flushing by 3% against zero. A vasoconstrictor for redness that causes redness in a measurable minority is a genuinely awkward product, and the honest reading is that it works well for most people and fails badly for some.
Everything else is ordinary and well documented: 553 subjects, four weeks, identical trial designs, both salt and free-base strengths stated, 99% Caucasian. Around $168 with a discount card against an average retail near $480. If you are going to try it, try it knowing what the failure mode is and having agreed with a prescriber what you do if it happens.
- Two identical randomised vehicle-controlled trials with a demanding four-timepoint composite endpoint.
- Every timepoint in both trials published with the vehicle arm beside it.
- Roughly double Rhofade's composite success on an endpoint constructed the same way.
- Both salt and free-base concentrations stated.
- States explicitly that some trial subjects experienced erythema returning worse than baseline.
- Publishes an adverse reaction table showing its own drug causing erythema and flushing more than vehicle.
- Reports the total exposed population — 1,210 subjects — not only the controlled cohort.
- A generic is available.
- A rebound phenomenon is recorded in the label, without a rate attached to it.
- Erythema in 4% of subjects against 1% on vehicle; flushing in 3% against zero.
- Controlled trials ran 29 days for a lifelong condition.
- 99% of subjects were Caucasian.
- Treats appearance, not disease — vasoconstriction wears off.
- No guidance anywhere on how to stop, taper or manage rebound if it occurs.
- Average retail near $480.
- Nothing on the label about combining it with treatment for the inflammatory component.
Every active, assessed
- Brimonidine tartrate0.33% — 5 mg/g tartrate, 3.3 mg/g free base
Alpha-2 adrenergic agonist — constricts cutaneous vessels, reducing visible erythema
- BENCHMARK
- 0.33% is the approved and trialled concentration
- ASSESSMENT
- Correctly dosed, with both the salt and free-base concentrations stated — the same precision Rhofade shows and almost nothing compounded manages. The pharmacology is also the problem: sustained alpha-2 agonism at the same vascular bed daily is the plausible mechanism for the tachyphylaxis and rebound the label records, and no dosing schedule in the label is designed to avoid it.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| Brimonidine tartrateAlpha-2 adrenergic agonist — constricts cutaneous vessels, reducing visible erythema | 0.33% — 5 mg/g tartrate, 3.3 mg/g free base | 0.33% is the approved and trialled concentration | Correctly dosed, with both the salt and free-base concentrations stated — the same precision Rhofade shows and almost nothing compounded manages. The pharmacology is also the problem: sustained alpha-2 agonism at the same vascular bed daily is the plausible mechanism for the tachyphylaxis and rebound the label records, and no dosing schedule in the label is designed to avoid it. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%60/100
Two identical randomised vehicle-controlled trials in 553 subjects with a demanding four-timepoint composite endpoint, consistent across both. The effect is roughly double Rhofade's on the same endpoint construction. Marked down hard because the trials ran 29 days for a condition managed over decades, because 99% of subjects were Caucasian, and because the label records a rebound phenomenon without quantifying how often it occurred.
- FORMULATION INTEGRITYWEIGHT 20%70/100
A conventional once-daily aqueous gel at the trialled strength, both concentrations stated, full excipient list, pharmaceutical manufacture. Nothing about the vehicle is doing therapeutic work, and nothing in the formulation addresses the tachyphylaxis its own pharmacology invites.
- DISCLOSUREWEIGHT 15%90/100
Publishes the composite endpoint at every timepoint in both trials with the vehicle arm beside it, the total exposed population of 1,210 subjects, the adverse reaction table showing its own drug causing erythema and flushing more than vehicle, and — the important one — an explicit statement that some subjects had erythema return worse than baseline. Marked down only because the rebound is described without a rate.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed, and it is the criterion that decides this product. A third of treated subjects had at least one adverse reaction against 28% on vehicle, and the specific reactions that matter — erythema and flushing — are the ones the drug is sold to prevent. A panel would need to run well beyond 29 days to say anything useful.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed, and it matters: a daytime gel worn under sunscreen and make-up for twelve hours.
- COST PER APPLICATIONWEIGHT 10%40/100
From around $168 with a discount card against an average retail near $480, with a generic available and fill weights published. Cheaper than Rhofade and more effective on paper — but a product whose failure mode is making the presenting complaint worse is hard to price fairly at any figure.
What it is
Brimonidine tartrate 0.33% in a once-daily aqueous facial gel, an alpha-2 adrenergic agonist approved for the persistent, non-transient erythema of rosacea in adults. It was the first drug approved for that indication, and it is the comparator R-41 named but did not review.
On paper, it beats the alternative
Both approved erythema drugs were tested against the same endpoint construction: a two-grade improvement on both the clinician's and the patient's erythema scale, measured at hours 3, 6, 9 and 12 on day 29. That makes the comparison unusually fair for two separate registration programmes.
Mirvaso study 1: N=129 against 131. Study 2: N=148 against 145. Rhofade's figures at R-41, on the same endpoint construction, ran from 12% to 18%. Different trials, different populations — but the same test, and the older drug does better on it.
Roughly one user in four reached a two-grade improvement on both scales twelve hours after applying it. That is still not most people — the honest framing of this whole drug class is that it helps a minority substantially — but it is meaningfully better than the newer alternative.
And then section 5
Some subjects in the clinical trials discontinued use of MIRVASO topical gel because of erythema. Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline.
FDA-approved labelling, Warnings and Precautions
This is not an internet rumour that made it onto a label. It is a finding from the registration trials, printed in the warnings section, and it is the reason many prescribers moved to oxymetazoline despite its weaker numbers. What the label does not do is quantify it — there is no percentage, no time-to-onset, no predictor of who it happens to, and no guidance on management. A patient is told the failure mode exists and given nothing to act on.
The adverse reaction table corroborates it from the other side. Among 330 subjects treated for 29 days: erythema in 12 subjects, 4%, against 3 on vehicle at 1%. Flushing in 9 subjects, 3%, against zero. A third of treated subjects had at least one adverse reaction, against 28% on vehicle.
There is a plausible pharmacological account. Sustained alpha-2 agonism at the same vascular bed every day invites tachyphylaxis, and when the constriction fails the vessels do not simply return to baseline. Nothing in the dosing schedule is designed around that, and 29-day trials are too short to characterise it properly.
Twenty-nine days
Both controlled trials ran for four weeks. Rosacea is managed for decades. That mismatch is not unique to this product — Rhofade's controlled trials also ran 29 days — but it lands harder here, because the specific concern with brimonidine is what happens with continued daily use, and continued daily use is exactly what the trials did not test.
The label does record that 1,210 subjects were exposed to the drug across the programme, and 833 of those were treated for the erythema indication. What it does not do is report outcomes for the ones treated longest, which is the analysis that would settle the question.
If you are considering it
- Treat the inflammatory component first — R-40 and R-42 do far more for papules and pustules than this does for redness.
- Read the rebound paragraph and agree with your prescriber, before you start, what you do if it happens.
- Try it on a limited area first if your prescriber agrees, rather than the whole face.
- Once daily, a pea-sized amount, avoiding the eyes.
- Set a review point at four weeks — that is all the controlled data covers.
- Ask about generic brimonidine, and about the price, because the spread is nearly threefold.
- If your redness worsens, stop and seek advice rather than applying more.
- Nothing here substitutes for trigger work and daily photoprotection.
Where we stand
At 66 this scores above R-41 on efficacy and disclosure and below it on stance, which is the correct outcome. Mirvaso works better. Its failure mode is worse, it is documented on its own label, and it is unquantified.
Taken together, the two approved erythema drugs describe the state of the art honestly: one helps roughly a quarter of users for part of a day and can rebound; the other helps roughly a sixth and, on the available evidence, does not. Neither treats rosacea. Anyone being sold a cream that promises to take the redness away permanently is being sold something that no regulator has ever seen evidence for.
The other approved erythema drug — weaker numbers, no recorded rebound.
The same manufacturer's rosacea product, and the strongest evidence base in the register.
Why the 9% to 11% vehicle column matters as much as the drug column.
Who this is for
- Someone whose persistent facial erythema is genuinely disabling and who has already treated the inflammatory component.
- Someone who will trial it deliberately, for a defined period, with a plan for what happens if redness worsens.
- Someone who has tried the alternative at R-41 and found it did nothing.
- Someone whose prescriber has explicitly discussed rebound with them.
- You are not prepared for the possibility that your redness comes back worse than it started.
- Your rosacea is primarily papules and pustules — R-40 and R-42 treat that far better.
- You want a treatment that changes the condition rather than its appearance for part of a day.
- You want evidence beyond a month, which this label does not offer for the controlled cohort.
- You are paying anything near average retail.
We earn nothing on this link. Read the rebound paragraph before you fill this, and agree in advance what you do if your redness comes back worse.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01FDA-approved labelling — MIRVASO (brimonidine) topical gel, 0.33%, Galderma Laboratories, L.P. The 0.33% strength stated as 5 mg of brimonidine tartrate and 3.3 mg of free base per gram; the two identical 29-day vehicle-controlled trials in 553 subjects with two-grade composite success at hours 3, 6, 9 and 12 on day 29 (31%/30%/26%/23% against 11%/10%/10%/9% in study 1; 25%/25%/18%/22% against 9%/9%/11%/10% in study 2); the demographic composition of 99% Caucasian and 76% female; the warning that some subjects discontinued because of erythema and that some reported a rebound phenomenon with erythema returning worse than baseline; and the adverse reaction table showing erythema in 4% against 1%, flushing in 3% against 0%, and at least one adverse reaction in 33% against 28%. Read 2 August 2026.
- S-02GoodRx — Mirvaso pricing Discount-card prices from around $167.75 against an average retail price near $479.93. Retrieved 2 August 2026.